March 2021: Predicting prognosis of breast cancer patients with brain metastases


An analysis including breast cancer patients with brain metastases from the BMBC registry has been published in Cancers

The incidence of brain metastases from breast cancer is increasing and the treatment is still a major challenge. Several scores have been developed in order to estimate the prognosis of patients with brain metastases by objective criteria. The aim of this study was to validate all three available graded-prognostic-assessment (GPA)-scores: original GPA, the breast-GPA and the updated breast-GPA in a cohort of 882 breast cancer patients with brain metastases from the Brain Metastases in the German Breast Cancer (BMBC) registry. The median age at diagnosis of brain metastases was 57 years, 22.3% of patients (n=197) had triple-negative, 33.4% (n=295) luminal A like, 25.1% (n=221) luminal B/HER2-enriched like and 19.2% (n=169) HER2-positive like breast cancer. The median overall survival (OS) in the cohort was 8.7 months. All three GPA-scores were associated with OS. Age ≥60 years, evidence of extracranial metastases, higher number of brain metastases, triple-negative subtype and low Karnofsky-Performance-Status were all associated with worse OS in univariate analysis (p< 0.001 each). The breast-GPA showed the highest probability of classifying patients with survival above 12 months in the best prognostic group (specificity 68.7% compared with 48.1% for the updated breast-GPA and 21.8% for the original GPA). Sensitivities for predicting 3 months survival were very low for all scores. In this analysis, all GPA-scores showed only moderate diagnostic accuracy in predicting the OS of BC patients with brain metastases. This analysis is of clinical relevance in the context of potential trials examining the benefit of early detection and treatment of brain metastases.

Riecke K, Müller V, Weide R, et al. Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry-Comparison of Three Different GPA Prognostic Scores. Cancers (Basel). 2021 Feb 17;13(4):844.


  • 18.11.2022 Desiree: dose escalation of everolimus published

    Desiree: dose escalation of everolimus published

    We are proud to inform you that our article A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE; GBG 86) is now available online.

    Mehr ...
  • 10.11.2022 Deutscher Krebskongress

    Deutscher Krebskongress

    Die GBG ist mit mehreren Postern auf dem 35. Deutschen Krebskongress vom 13. – 16. November 2022 in Berlin vertreten.

    Mehr ...
  • 08.11.2022 GBG research at SABCS 2022

    GBG research at SABCS 2022

    We are proud to present our research at the San Antonio Breast Cancer Symposium, December 6-10

    Mehr ...
  • 14.10.2022 Location of Subcutaneous Trastuzumab Injection

    Location of Subcutaneous Trastuzumab Injection

    Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: pharmacokinetic, safety and patients´ preference - substudy of the randomised phase III GAIN-2 study

    Mehr ...

GBG Forschungs GmbH
Dornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd